Phase 3 RCT in 203 patients with CML in deep molecular remission stopping TKIs: ropeginterferon alfa-2b did not improve 25-month molecular relapse-free survival vs observation (56% vs 59%; HR 1.02, P=0.91). Of 83 with data after TKI restart, 95% regained MMR.
RCTn = 203
Burchert et al. Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX)